ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2127

Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission

Y.Y.J. Gent1, M.M. ter Wee1, D den Uyl1, N. Ahmadi2, W.F. Lems3, O.S. Hoekstra4, A.E. Voskuyl1 and C.J. Van der Laken3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU Medical Center, Amsterdam, Netherlands, 4Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Imaging, Macrophage, positron emission tomography (PET), remission and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Imaging of Rheumatic Diseases: Various Imaging Techniques

Session Type: Abstract Submissions (ACR)

Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical synovitis can still be present despite clinical remission and has been linked to ongoing radiological damage. Our group has shown that positron emission tomography with macrophage targeting (11C-(R)-PK11195 PET) is a highly sensitive and specific technique to visualize (subclinical) arthritis activity. In the current study we investigated if 11C-(R)-PK11195 PET can depict residual disease activity in early RA patients who reached CR and whether the inflammatory activity on the scans was associated with the development of a flare (as compared to MRI).

Methods: 11C-(R)-PK11195 PET (HRRT, CTI/Siemens) of hands/wrists was performed in 25 RA patients that had no tender or swollen joints after treatment with combined DMARD therapy (DAS44<1.6). (R)–11C-PK11195 uptake (visual score: 0 (low)-3 (high)) in metacarpophalangeal, proximal interphalangeal and wrist joints (n=22 joints/patient) was scored and corrected for background uptake. Individual joint scores were summed to obtain a cumulative PET score (range 0-66). Follow-up duration was 1 year after PET.  Flare of clinical disease activity was defined as ³ 1 swollen joint. Results: Of the included patients, 14 out of 25 (56%) developed a clinical flare of arthritis anywhere within 1 year of follow-up. (R)–11C-PK11195 PET showed enhanced tracer uptake in at least one scanned joint in 11/25 (44%) patients. Cumulative PET scores of patients developing a flare tended to be higher than that of patients without a flare (median (IQR) 1 (0-4) vs 0 (0-1), p=ns) (Fig left).  Within the flare subgroup, patients with a flare in hands/wrists (n=6),  had significantly higher cumulative PET scores than patients without a flare (n=11)(p=0.04). Patients with a cumulative PET score of 4 and higher, all developed arthritis in hands/wrists within 6 months. As comparison, MRI scans of all included patients were positive regardless of flaring, not distinguishing between subgroups of flare and no flare (Fig right).

Conclusion: Macrophage targeting by (R)–11C-PK11195 PET can visualize subclinical synovitis in hand/wrist joints of drug-induced remission in early RA. Uptake of (R)–11C-PK11195 was higher in patients with with a flare compared to those without a flare. High cumulative PET scores seem to be associated with short-term development of flare. In comparison to MRI, PET may have superior diagnostic value with respect to specificity. Larger cohort studies are needed to confirm these data.


Disclosure:

Y. Y. J. Gent,
None;

M. M. ter Wee,
None;

D. den Uyl,
None;

N. Ahmadi,
None;

W. F. Lems,
None;

O. S. Hoekstra,
None;

A. E. Voskuyl,
None;

C. J. Van der Laken,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subclinical-arthritis-is-detected-by-macrophage-targeting-and-positron-emission-tomography-pet-in-early-ra-patients-in-clinical-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology